TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Screening and Treatment for PTSD in SUD Patients
Brief Summary: This study proposes a prospective program of research that will identify feasible and inexpensive methods to detect and treat comorbid PTSD among VA SUD patients, thereby improving substance abuse treatment outcomes.


Options:
A: Arm Label: Seeking Safety; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Modified Seeking Safety integrated into std outpatient SUD care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard outpatient SUD care | Intervention Type: BEHAVIORAL; Name: Modified Seeking Safety integrated into std outpatient SUD care; Assigned to Arm(s): Seeking Safety | Intervention Type: BEHAVIORAL; Name: Standard outpatient SUD care; Assigned to Arm(s): Usual Care
B: Arm Label: Naltrexone alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: Naltrexone with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy, Drug: Naltrexone | Arm Label: Placebo with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Placebo alone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Naltrexone with CBT for PTSD, Placebo with CBT for PTSD | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone alone, Naltrexone with CBT for PTSD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo alone
C: Arm Label: 1) CDM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Chronic Disease Management for substance abuse | Arm Label: 2) Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Chronic Disease Management for substance abuse; Assigned to Arm(s): 1) CDM | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 2) Standard care
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2
Brief Summary: PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to maintenance therapy with bevacizumab+erlotinib alone after an induction therapy combining bevacizumab+chemotherapy in treating patients with metastatic colorectal cancer that cannot be removed by surgery.


Options:
A: Arm Label: Arm B: FOLFOXIRI & bevacizumab (inclusion completed); Type: EXPERIMENTAL; Interventions: Drug: FOLFOXIRI with bevacizumab | Arm Label: Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed); Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Arm Label: Arm D: FOLFOX/FOLFIRI & panitumumab; Type: EXPERIMENTAL; Interventions: Drug: FOLFOX/ FOLFIRI with panitumumab | Arm Label: Arm C: FOLFOX/ FOLFIRI & bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with bevacizumab; Assigned to Arm(s): Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed), Arm C: FOLFOX/ FOLFIRI & bevacizumab | Intervention Type: DRUG; Name: FOLFOXIRI with bevacizumab; Assigned to Arm(s): Arm B: FOLFOXIRI & bevacizumab (inclusion completed) | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with panitumumab; Assigned to Arm(s): Arm D: FOLFOX/FOLFIRI & panitumumab
B: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib
C: Arm Label: Panitumumab Plus mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: mFOLFOX6 | Arm Label: Bevacizumab Plus mFOLFOX6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: mFOLFOX6 | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus mFOLFOX6 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab Plus mFOLFOX6 | Intervention Type: DRUG; Name: mFOLFOX6; Assigned to Arm(s): Bevacizumab Plus mFOLFOX6, Panitumumab Plus mFOLFOX6
D: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation
Brief Summary: The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.


Options:
A: Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Thioguanine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Autologous stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Allogeneic stem cell transplantation; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: liposomal daunorubicin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anthracyclines | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: 2-CDA | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: AI | Intervention Type: DRUG; Name: Anthracyclines; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: liposomal daunorubicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 2-CDA; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AI; Assigned to Arm(s): 4
D: Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cytosin-Arabinosid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: All-trans Retinoid acid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Homocysteine-lowering With B Vitamins for Secondary Prevention of Cardiovascular Disease After Acute Myocardial Infarction. The Norwegian Vitamin Trial (NORVIT)
Brief Summary: The purpose of this study is to examine whether the lowering of blood homocysteine levels by treatment with B vitamins can prevent cardiovascular disease


Options:
A: Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Homocysteine-lowering With B Vitamins for Secondary Prevention of Cardiovascular Disease After Acute Myocardial Infarction. The Norwegian Vitamin Trial (NORVIT)
Brief Summary: The purpose of this study is to examine whether the lowering of blood homocysteine levels by treatment with B vitamins can prevent cardiovascular disease


Options:
A: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
C: Arm Label: High Dose Multivitamin; Type: EXPERIMENTAL; Interventions: Drug: High Dose Multivitamin | Arm Label: Low Dose Multivitamin; Type: ACTIVE_COMPARATOR; Interventions: Device: Low Dose Multivitamin | Intervention Type: DRUG; Name: High Dose Multivitamin; Assigned to Arm(s): High Dose Multivitamin | Intervention Type: DEVICE; Name: Low Dose Multivitamin; Assigned to Arm(s): Low Dose Multivitamin
D: Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen
Brief Summary: Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV


Options:
A: Arm Label: MK-8237; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 tablets, Drug: Rescue Medication: Self-Injectable Epinephrine, Drug: Rescue Medication: Loratadine tablets, Drug: Rescue Medication: Olopatadine ophthalmic drops, Drug: Rescue Medication: Mometasone furoate nasal spray | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo tablets, Drug: Rescue Medication: Self-Injectable Epinephrine, Drug: Rescue Medication: Loratadine tablets, Drug: Rescue Medication: Olopatadine ophthalmic drops, Drug: Rescue Medication: Mometasone furoate nasal spray | Intervention Type: BIOLOGICAL; Name: MK-8237 tablets; Assigned to Arm(s): MK-8237 | Intervention Type: BIOLOGICAL; Name: Placebo tablets; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Rescue Medication: Self-Injectable Epinephrine; Assigned to Arm(s): MK-8237, Placebo | Intervention Type: DRUG; Name: Rescue Medication: Loratadine tablets; Assigned to Arm(s): MK-8237, Placebo | Intervention Type: DRUG; Name: Rescue Medication: Olopatadine ophthalmic drops; Assigned to Arm(s): MK-8237, Placebo | Intervention Type: DRUG; Name: Rescue Medication: Mometasone furoate nasal spray; Assigned to Arm(s): MK-8237, Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: BIOLOGICAL; Name: Recombinant birch pollen; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: ALK HDM tablet; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Kansas University DHA Outcome Study (KUDOS)
Brief Summary: The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexaenoic acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexaenoic acid (DHA); Assigned to Arm(s): 2
B: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
C: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: MicroLipid and fish oil | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine care | Intervention Type: DIETARY_SUPPLEMENT; Name: MicroLipid and fish oil; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Routine care; Assigned to Arm(s): Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Kansas University DHA Outcome Study (KUDOS)
Brief Summary: The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.


Options:
A: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm
B: Arm Label: Low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Arm Label: Low dose aspirin plus omega 3 group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin, Drug: Omega 3 | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Low dose aspirin, Low dose aspirin plus omega 3 group | Intervention Type: DRUG; Name: Omega 3; Assigned to Arm(s): Low dose aspirin plus omega 3 group
C: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
D: Arm Label: Docosa-hexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Docosa-hexaenoic acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosa-hexaenoic acid (DHA); Assigned to Arm(s): Docosa-hexaenoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Kansas University DHA Outcome Study (KUDOS)
Brief Summary: The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.


Options:
A: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexaenoic acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexaenoic acid (DHA); Assigned to Arm(s): 2
C: Arm Label: standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: modified infant formula; Type: EXPERIMENTAL; Interventions: Other: modified infant formula | Arm Label: breast milk; Type: OTHER; Interventions: Other: breast milk | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): standard infant formula | Intervention Type: OTHER; Name: modified infant formula; Assigned to Arm(s): modified infant formula | Intervention Type: OTHER; Name: breast milk; Assigned to Arm(s): breast milk
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 4; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: DHA and ARA; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Kansas University DHA Outcome Study (KUDOS)
Brief Summary: The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: omega 3 fatty acids | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: vegetable oil | Intervention Type: DIETARY_SUPPLEMENT; Name: omega 3 fatty acids; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: vegetable oil; Assigned to Arm(s): 2
B: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
C: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
D: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Brief Summary: The goal of this clinical research study is to learn if lenalidomide (Revlimid®) can help to control CLL in patients who have already received standard therapy. The safety of lenalidomide will also be studied.


Options:
A: Arm Label: IBR + OB; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Obinutuzumab | Arm Label: CLB + OB; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): IBR + OB | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): CLB + OB, IBR + OB | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): CLB + OB
B: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Lenalidomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A (CLL/SLL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Arm Label: Arm B (NHL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Intervention Type: DRUG; Name: ABT-199; Assigned to Arm(s): Arm A (CLL/SLL subjects), Arm B (NHL subjects)
D: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Brief Summary: Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heartbeat, sometimes a pacemaker is used to control the rate and rhythm of the heartbeat. In this trial, the researchers will test if pacing both the left and right lower half of the heart (ventricles) will:

* decrease the number of hospital and clinic visits due to heart failure symptoms
* extend life
* delay heart failure symptoms as compared to those who are paced in only one ventricle (the right ventricle)


Options:
A: Arm Label: Traditional ICD Programming; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional ICD Programming | Arm Label: Ultra Conservative ICD Programming; Type: EXPERIMENTAL; Interventions: Other: Ultra Conservative ICD Programming | Intervention Type: OTHER; Name: Ultra Conservative ICD Programming; Assigned to Arm(s): Ultra Conservative ICD Programming | Intervention Type: OTHER; Name: Traditional ICD Programming; Assigned to Arm(s): Traditional ICD Programming
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: ICD | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal medical treatment | Intervention Type: DEVICE; Name: ICD; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Optimal medical treatment; Assigned to Arm(s): B
C: Arm Label: Biventricular pacing; Type: EXPERIMENTAL; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Arm Label: Right ventricular pacing; Type: ACTIVE_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Biventricular pacing | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Right ventricular pacing
D: Arm Label: CRT OFF; Type: PLACEBO_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT | Arm Label: CRT ON; Type: ACTIVE_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT; Assigned to Arm(s): CRT OFF, CRT ON

Answer: C